Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group.
about
Emergence of unusual species of enterococci causing infections, South IndiaMolecular analysis and distribution of multidrug-resistant Enterococcus faecium isolates belonging to clonal complex 17 in a tertiary care center in Mexico CityMolecular analysis of Tn1546 in Enterococcus faecium isolated from animals and humansCharacterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptidesUse of molecular and reference susceptibility testing methods in a multicenter evaluation of MicroScan dried overnight gram-positive MIC panels for detection of vancomycin and high-level aminoglycoside resistances in enterococci.Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditisEnterococci: new aspects of an old organism.Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristinComparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium.In vitro activities of 15 antimicrobial agents against clinical isolates of South African enterococci.Pharmacologic and bacteriologic properties of SCH-27899 (Ziracin), an investigational antibiotic from the everninomicin family.Comparison of direct plating and broth enrichment culture for the detection of intestinal colonization by glycopeptide-resistant enterococci among hospitalized patients.Ability of laboratories to detect emerging antimicrobial resistance: proficiency testing and quality control results from the World Health Organization's external quality assurance system for antimicrobial susceptibility testing.Heteroresistance to vancomycin in Enterococcus faecium.Antimicrobial susceptibility patterns of enterococci causing infections in Europe. The European VRE Study Group.Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents.Sequential emergence of antibiotic resistance in enterococcal bloodstream isolates over 25 years.Vancomycin-resistant enterococci: mechanisms and clinical observations.Decision-making on the use of antimicrobial prophylaxis for dental procedures: a survey of infectious disease consultants and review.In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinonesSemisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococciIn vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci.In vitro activity and spectrum of LY333328, a novel glycopeptide derivative.Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium.Healthcare-associated vancomycin resistant Enterococcus faecium infections in the Mansoura University Hospitals intensive care units, EgyptEmergence of clonal complex 17 Enterococcus faecium in The Netherlands.Vancomycin-resistant enterococci colonizing the intestinal tracts of hospitalized patients.Outcomes for and risk factors associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant Enterococcus faecium bacteremia in cancer patients.Pharmacokinetics of an everninomicin (SCH 27899) in mice, rats, rabbits, and cynomolgus monkeys following intravenous administration.Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999.Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin.Modified pulsed-field gel electrophoresis protocol for typing of enterococci.Clonal dissemination of VanA-type glycopeptide-resistant Enterococcus faecalis between hospitals of two cities located 100 km apart.
P2860
Q24806424-3152AFB0-EE9F-48C6-BD42-F84E6500D6F7Q33644179-7B46DD4E-AD2A-49C0-8389-3124164E925EQ33656106-60759861-29D5-417B-BF6C-FF74509774B3Q33661713-A1BE7637-3F34-4213-B2D0-D029EA8ED5A1Q33679146-14335754-0C3E-4C22-9EF0-DFE95C749583Q33693084-8E42A934-E04F-43C7-97F8-9634CFE00C2DQ33694086-9685C634-B88F-47B7-BDD6-315B0DF02FD7Q33695217-A834141D-CDB3-4BCE-A513-4A1789D5446DQ33698979-45CF81B0-D698-456F-BD91-509188CCE588Q33700343-E19A868F-1E6E-4008-9B3C-E216E6E7C2AEQ33747136-17F87274-BD7C-4A84-9841-C3745B71253BQ33960216-0958AE65-50F0-41BD-88D1-065830A09202Q33970955-635DAB39-90FC-4656-B085-22078BB84312Q33973499-12598D88-13FF-42C8-BCAD-ED53806C2889Q33977918-6BC7E243-0F2A-4786-85B2-7088C74E8D8EQ33978122-FB1A033A-A25F-44E6-8253-E543058676FBQ34142606-A2A97F10-5BAF-48F0-AB4C-AAB9FE3B4129Q34289227-71E85FA7-C378-42B7-8BC7-53752EF26215Q34658654-F0A93D57-8925-4A64-9586-0C9461517318Q35123200-F7D84430-24A7-4734-B34F-4FAA33A2226DQ35127151-1355880C-AC02-4A7E-A7A3-762DABF8A5B0Q35128490-344D9591-E987-4420-8302-712464A21324Q35133106-9E665C66-EB34-40AE-AED3-055AEDEEDA1DQ35139489-593C83FB-B0C4-4014-A049-51E28E2791DCQ36057341-6B2A96C2-A1B8-4BF7-A6EA-6499C101E76BQ36423673-602C3E96-3940-4BD4-891A-CFE2F3C57518Q36525679-95DB37C6-59EA-4044-A9B4-674B4DD2BC4DQ36969233-D6FB3DFC-597D-4FC6-BEDB-BA8A8FE2088FQ39473429-BF19AFF5-286E-4CC7-B316-14D46E562F36Q43587155-5E34A09F-D300-4C31-82A2-7BAEB320AAE8Q43773396-12548295-FDE1-4694-AA71-56342313656FQ44367883-033AB512-A413-42DE-825D-2EAB333F4F02Q45034700-FD2601A7-5BAD-4E34-B24E-5F7EED571470
P2860
Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Emerging multiply resistant en ...... tes. Enterococcus Study Group.
@ast
Emerging multiply resistant en ...... tes. Enterococcus Study Group.
@en
type
label
Emerging multiply resistant en ...... tes. Enterococcus Study Group.
@ast
Emerging multiply resistant en ...... tes. Enterococcus Study Group.
@en
prefLabel
Emerging multiply resistant en ...... tes. Enterococcus Study Group.
@ast
Emerging multiply resistant en ...... tes. Enterococcus Study Group.
@en
P2093
P1476
Emerging multiply resistant en ...... tes. Enterococcus Study Group.
@en
P2093
P356
10.1016/0732-8893(94)00147-O
P577
1995-02-01T00:00:00Z